FDA approves RevMed’s Rasonque to slow pancreatic cancer
In a late-stage study, RevMed’s Rasonque helped subjects live to 13 months, nearly twice as long as chemotherapy alone. US regulators approved the drug to slow pancreatic cancer.
In a late-stage study, RevMed’s Rasonque helped subjects live to 13 months, nearly twice as long as those who only received chemotherapy.
US regulators on Wednesday approved a drug that slows pancreatic cancer, a breakthrough treatment for a disease that kills seven out of eight patients within five years.
In a late-stage study, RevMed’s Rasonque helped subjects live to 13 months, nearly twice as long as those who only received chemotherapy. “ This is life-altering,” an oncologist told The Wall Street Journal.
Researchers spent decades trying to target a group of mutations called RAS — responsible for nearly a third of all human cancers — but the protein’s flat shape defied typical drugs.
RevMed designed a new “ molecular glue ” that latched onto a pocket on the protein.
Rasonque could generate more than $20 billion in annual sales, a pharma analytics firm forecast.